Tuftsin is the tetrapeptide
Thr-Lys-Pro-Arg. It is spontaneously released from the
Fc fragment of
IgG by two specific
enzymes. One 25-micrograms dose administered to mice in good immunologic status stimulated phagocytosis, macrophage killing of
tumor cells,
delayed hypersensitivity, cytolytic T-cell activity, antibody production, antibody-dependent cell-mediated cytotoxicity (ADCC), and natural killer (NK) cell activity. Administered for 6 months at the dose of 10 micrograms once a week to old, immunodepressed mice,
tuftsin restored macrophage and T-cell cytotoxic activities. At this dosage,
tuftsin prevented spontaneous
tumor development.
Tuftsin was also well tolerated in phase I studies in humans in increased polymorphonuclear leukocytes and OKT4-positive lymphocytes.
Bestatin is extracted from Streptomyces olivoreticuli. One 100-micrograms dose of
bestatin injected in young mice with normal immunologic status increased macrophage cytotoxicity, antibody production, ADCC, and NK cell activities. Long-term administration of
bestatin (100 micrograms once a week) corrected macrophage and T-cell cytotoxicity and prevented age-related spontaneous
tumors.
Bestatin inhibited lymphocyte membrane
aminopeptidase, which degrades
tuftsin into a tripeptide that is an antagonist competing with it for receptors.
Tuftsin and
bestatin constitute a biopharmacologic system that can be developed as other
aminopeptidase inhibitors are available for study.